Psychedelic Spotlight News

  • MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)

    Listen, Videos

    Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!

    Timestamps:

    0:00 – Intro
    1:00 – MindMed Begins a Mescaline Study
    4:35 – MindMed & The Chopra Foundation
    8:30 – Cybin Progresses Phase 2a psilocybin study
    11:56 – Mydecine announces Q1 Financials
    14:16 – Havn Life Sciences enters the Cluster Headaches Game
    16:30 – Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression

    Enjoy!
    Links:
    MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
    https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/

    MindMed Partners Up with The Chopra foundation:
    https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/

    Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
    https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/

    Mydecine (MYCO / MYCOF) Q1 Financials:
    https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update

    Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
    https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/

    Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
    https://psychedelicspotlight.com/wake-psilocybin-microdose-study/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifa…

    https://benzinga.grsm.io/thepsychedel…

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #HAVN

  • Interview With Dr. Gorman

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies (“MAPS”).ya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.